Email Alert RSS
Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Abstract
References
CHEN Yue. Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 187-191. DOI: 10.12290/xhyxzz.2021-0557
Citation: CHEN Yue. Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 187-191. DOI: 10.12290/xhyxzz.2021-0557
shu

Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China

  • Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

Funds: 

National Natural Science Foundation of China U20A20384

More Information
  • Corresponding author:

    CHEN Yue, E-mail: chenyue5523@126.com

  • Received Date: July 25, 2021
  • Accepted Date: November 21, 2021
  • Available Online: November 22, 2021
  • Issue Publish Date: March 29, 2022
    Graphical Abstract
    • Abstract
  • Theranostics in nuclear medicine is the combination of radionuclide imaging and internal radiotherapy, so as to realize the visualized diagnosis and precise treatment of diseases. At present, theranostics of nuclear medicine has played an important role in differentiated thyroid carcinoma, pheochromocytoma, bone metastases, neuroendocrine tumors and prostate cancer. China's medical radionuclides and radionuclide medicines are in short supply and heavily dependent on imports, so there is a "bottleneck" problem. It is necessary to strengthen the independent production, innovation and research of medical radionuclides and radiopharmaceutics of theranostics, so as to promote theranostics of nuclear medicine to better serve China's clinical practice.
    • FullText(HTML)
    • References (34)
  • [1]
    Filippi L, Chiaravalloti A, Schillaci O, et al. Theranostic approaches in nuclear medicine: current status and future prospects[J]. Expert Rev Med Devices, 2020, 17: 331-343. DOI: 10.1080/17434440.2020.1741348
    [2]
    Jokar N, Assadi M, Yordanova A, et al. Bench-to-Bedside Theranostics in Nuclear Medicine[J]. Curr Pharm Des, 2020, 26: 3804-3811. DOI: 10.2174/1381612826666200218104313
    [3]
    Solnes LB, Shokeen M, Pandit-Taskar N. Novel Agents and Future Perspectives on Theranostics[J]. Semin Radiat Oncol, 2021, 31: 83-92. DOI: 10.1016/j.semradonc.2020.07.010
    [4]
    O'Dwyer E, Bodei L, Morris MJ. The Role of Theranostics in Prostate Cancer[J]. Semin Radiat Oncol, 2021, 31: 71-82. DOI: 10.1016/j.semradonc.2020.07.004
    [5]
    张锦明, 杜进. 中国放射性药物制备的现状及展望[J]. 同位素, 2019, 32: 178-185. DOI: 10.7538/tws.2019.32.03.0178

    Zhang JM, Du J. Preparation of Radiopharmaceuticals in China: Current Status and Prospects[J]. Tongweisu, 2019, 32: 178-185. DOI: 10.7538/tws.2019.32.03.0178
    [6]
    Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1588-1601. DOI: 10.1007/s00259-017-3728-y
    [7]
    Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. DOI: 10.1056/NEJMoa1607427
    [8]
    Ali N, Sebastian C, Foley RR, et al. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy[J]. Nucl Med Commun, 2006, 27: 165-169. DOI: 10.1097/01.mnm.0000194397.20067.b6
    [9]
    Nagarajah J, Janssen M, Hetkamp P, et al. Iodine Symporter Targeting with 124I/131I Theranostics[J]. J Nucl Med, 2017, 58: 34S-38S. DOI: 10.2967/jnumed.116.186866
    [10]
    Gulec SA, Kuker RA, Goryawala M, et al. 124I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis[J]. Thyroid, 2016, 26: 441-448. DOI: 10.1089/thy.2015.0482
    [11]
    Furuta N, Kiyota H, Yoshigoe F, et al. Diagnosis of pheochromocytoma using[123I]-compared with[131I]-metaiodobenzylguanidine scintigraphy[J]. Int J Urol, 1999, 6: 119-124. DOI: 10.1046/j.1442-2042.1999.06310.x
    [12]
    Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma[J]. J Nucl Med, 2019, 60: 623-630. DOI: 10.2967/jnumed.118.217463
    [13]
    Willegaignon J, Crema KP, Oliveira NC, et al. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures[J]. Clin Nucl Med, 2018, 43: 572-578. DOI: 10.1097/RLU.0000000000002158
    [14]
    Weber M, Schmitz J, Maric I, et al. Diagnostic performance of 124I-m-iodobenzylguanidine PET/CT in patients with pheochromocytoma[J]. J Nucl Med, 2021. doi: 10.2967/jnumed.121.262797.
    [15]
    支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志, 2015, 37: 67-78. DOI: 10.3760/cma.j.issn.0253-3766.2015.01.014

    Zhi XY, Shi YK, Yu JM. Standards for the diagnosis and treatment of primary lung cancer(2015 version) in China[J]. Zhonghua Zhongliu Zazhi, 2015, 37: 67-78. DOI: 10.3760/cma.j.issn.0253-3766.2015.01.014
    [16]
    陈跃, 赵军, 吴湖炳, 等. 18F-NaF PET/CT骨显像操作指南[J]. 中华核医学与分子影像杂志, 2016, 36: 76-78. DOI: 10.3760/cma.j.issn.2095-2848.2016.01.018

    Chen Y, Zhao J, Wu HB, et al. Operation guide of 18F-NaF PET/CT bone imaging[J]. Zhonghua Heyixue Yu Fenzi Yingxiang Zazhi, 2016, 36: 76-78. DOI: 10.3760/cma.j.issn.2095-2848.2016.01.018
    [17]
    Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 846-859. DOI: 10.1007/s00259-018-3947-x
    [18]
    Manafi-Farid R, Masoumi F, Divband G, et al. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain[J]. J Clin Med, 2020, 9: 2622. DOI: 10.3390/jcm9082622
    [19]
    Sadremomtaz A, Masoumi M. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides[J]. J Med Imaging Radiat Sci, 2019, 50: 272-279. DOI: 10.1016/j.jmir.2018.12.005
    [20]
    Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT[J]. AJR Am J Roentgenol, 2018, 211: 267-277. DOI: 10.2214/AJR.18.19881
    [21]
    陈跃, 霍力, 兰晓莉, 等. 68Ga-DOTA-生长抑素受体PET/CT神经内分泌肿瘤显像操作指南[J]. 中国医学影像技术, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm

    Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-DOTA-conjugated somatostatin receptor PET/CT imaging in neuroendocrine neoplasms[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm
    [22]
    Zhang J, Song Q, Cai L, et al. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2020, 146: 1533-1543. DOI: 10.1007/s00432-020-03181-2
    [23]
    Farolfi A, Lima GM, Oyen W, et al. Molecular Imaging and Theranostics-A Multidisciplinary Approach[J]. Semin Nucl Med, 2019, 49: 247-254. DOI: 10.1053/j.semnuclmed.2019.02.002
    [24]
    Hamed M, Basha M, Ahmed H, et al. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy[J]. Acad Radiol, 2019, 26: 450-460. DOI: 10.1016/j.acra.2018.05.020
    [25]
    陈跃, 霍力, 兰晓莉, 等. 68Ga-前列腺特异性膜抗原PET/CT前列腺癌显像操作指南[J]. 中国医学影像技术, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm

    Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-PSMA PET/CT imaging in prostatic cancer[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm
    [26]
    Yadav MP, Ballal S, Sahoo RK, et al. Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis[J]. AJR Am J Roentgenol, 2019, 213: 275-285. DOI: 10.2214/AJR.18.20845
    [27]
    Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 2536-2544. DOI: 10.1007/s00259-019-04485-3
    [28]
    Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients[J]. Theranostics, 2020, 10: 9364-9377. DOI: 10.7150/thno.48107
    [29]
    Goldsmith SJ. Targeted Radionuclide Therapy: A Historical and Personal Review[J]. Semin Nucl Med, 2020, 50: 87-97. DOI: 10.1053/j.semnuclmed.2019.07.006
    [30]
    Jokar N, Velikyan I, Ahmadzadehfar H, et al. Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology[J]. Clin Nucl Med, 2021, 46: e410-e420. DOI: 10.1097/RLU.0000000000003678
    [31]
    Jadvar H. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies[J]. Cancer Biother Radiopharm, 2020, 35: 475-484. DOI: 10.1089/cbr.2019.3340
    [32]
    Brito AE, Etchebehere E. Radium-223 as an Approved Modality for Treatment of Bone Metastases[J]. Semin Nucl Med, 2020, 50: 177-192. DOI: 10.1053/j.semnuclmed.2019.11.005
    [33]
    Frantellizzi V, Cosma L, Brunotti G, et al. Targeted Alpha Therapy with Thorium-227[J]. Cancer Biother Radiopharm, 2020, 35: 437-445. DOI: 10.1089/cbr.2019.3105
    [34]
    Anand A, Trägårdh E, Edenbrandt L, et al. Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients[J]. J Nucl Med, 2020, 61: 671-675. DOI: 10.2967/jnumed.119.231100
    • Related Articles

  • Cited by

    Periodical cited type(10)

    1. 兰晓莉，宋祥铭. 放射性核素诊疗一体化:挑战与机遇. 中国医学影像技术. 2024(01): 3-6 .
    2. 国洪霞，潘栋辉，宿晨，徐宇平，王立振，严骏杰，王辛宇，陈重阳，杨慧，杨敏. ~(177)Lu标记HER2亲和体的制备及性能研究. 中华核医学与分子影像杂志. 2024(06): 330-336 .
    3. 刘国兵，卓维海，顾宇参，杨志，陈跃，樊卫，郭剑明，谭建，朱小华，霍力，兰晓莉，李彪，缪蔚冰，宋少莉，徐浩，田蓉，罗全勇，王峰，王雪梅，杨爱民，戴东，邓智勇，赵晋华，陈晓良，范岩，高再荣，韩星敏，蒋宁一，匡安仁，林岩松，刘甫庚，楼岑，苏新辉，唐立钧，王辉，王欣璐，杨福洲，杨辉，赵新明，杨波，黄晓冬，陈继亮，李思进，汪静，李亚明，石洪成. ~(177)Lu-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌临床应用专家共识. 中国临床医学. 2024(05): 844-851 .
    4. 沈水珍，黄中柯，赵徵鑫，王海华，廖燕. 真空排水技术在医院放射性废水排放系统改造中的应用初探. 中华放射医学与防护杂志. 2024(12): 1063-1068 .
    5. 武健，李兆全. ~(131)I对甲状腺癌切除术患者近期疗效及甲状腺激素水平的影响. 中国卫生标准管理. 2023(08): 90-94 .
    6. 周文媛，范洋，刘特立，陈卓，朱华，杨志. 放射性药物生产过程追溯体系的构建. 同位素. 2023(04): 416-422 .
    7. 雷蕾，杜涛，范冬梅，张瑜，郭春梅，黄占文. 微信随访管理在核素治疗恶性肿瘤病人居家护理中的应用效果. 西南医科大学学报. 2023(04): 348-351 .
    8. 闫志华，程兵，李祥周，陈伟娜. 锶-89联合碘-131在分化型甲状腺癌骨转移治疗中的效果. 河南医学研究. 2023(19): 3505-3508 .
    9. 吴福海，陈孟毅，王晓明，王春林，孙明月，邱珊珊，周佳骏，秦祥宇，沈浪涛. 发生器来源的氯化镓[~(68)Ga]溶液杂质研究. 原子能科学技术. 2023(10): 1889-1898 .
    10. 姜杨宏岩，冯蓓，于亚萍，赵倩. 靶向肿瘤微环境标志物及其分子影像学应用进展. 中国医学影像学杂志. 2022(12): 1309-1313 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2596) PDF downloads (765) Cited by(13)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close